Tokyo Tape
Sign in
← Fuso Pharmaceutical Industries

Annual report

4538.TEDINET S100YHSC
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
MetricValuePeriodScopeSource row
Revenue¥62.3bn2025-04-01 → 2026-03-31StandaloneNet sales
Revenue¥60.6bn2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥55.4bn2023-04-01 → 2024-03-31vStandaloneNet sales (5-year summary)
Revenue¥51.0bn2022-04-01 → 2023-03-31vStandaloneNet sales (5-year summary)
Revenue¥49.6bn2021-04-01 → 2022-03-31vStandaloneNet sales (5-year summary)
Operating income¥2.6bn2025-04-01 → 2026-03-31StandaloneOperating income
Operating income¥4.1bn2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income¥2.3bn2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income¥3.8bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥1.9bn2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥2.2bn2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥2.0bn2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax¥2.4bn2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax−¥5.0bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income¥2.0bn2025-04-01 → 2026-03-31StandaloneProfit loss
Net income−¥3.3bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥1.4bn2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income¥1.6bn2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥1.5bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥90.3bnat 2026-03-31StandaloneAssets
Total assets¥81.7bnat 2025-03-31StandaloneAssets
Total assets¥75.8bnat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥72.5bnat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥69.3bnat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥55.3bnat 2026-03-31StandaloneLiabilities
Total liabilities¥48.7bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥35.1bnat 2026-03-31StandaloneNet assets
Net assets / equity¥33.0bnat 2025-03-31StandaloneNet assets
Net assets / equity¥36.7bnat 2024-03-31vStandaloneNet assets
Net assets / equity¥35.6bnat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥34.5bnat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥4.8bnat 2026-03-31StandaloneCash and deposits
Cash and deposits¥6.3bnat 2025-03-31StandaloneCash and deposits
Cash & equivalents¥4.8bnat 2026-03-31StandaloneCash and cash equivalents
Cash & equivalents¥6.3bnat 2025-03-31StandaloneCash and cash equivalents
Cash & equivalents¥5.1bnat 2024-03-31vStandaloneCash and cash equivalents
Cash & equivalents¥8.0bnat 2023-03-31vStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥7.3bnat 2022-03-31vStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥6.2bn2025-04-01 → 2026-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥3.3bn2024-04-01 → 2025-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥627m2023-04-01 → 2024-03-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.9bn2022-04-01 → 2023-03-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.5bn2021-04-01 → 2022-03-31vStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥1.5bn2025-04-01 → 2026-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥3.2bn2024-04-01 → 2025-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥3.5bn2023-04-01 → 2024-03-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2022-04-01 → 2023-03-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.6bn2021-04-01 → 2022-03-31vStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥6.3bn2025-04-01 → 2026-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥7.6bn2024-04-01 → 2025-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥14m2023-04-01 → 2024-03-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥813m2022-04-01 → 2023-03-31vStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.7bn2021-04-01 → 2022-03-31vStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥235.632025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-384.952024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥159.982023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥183.072022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥169.092021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥902025-04-01 → 2026-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥822024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥702023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥702022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥602021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥4,106.51at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,869.1at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,290.55at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥4,064.76at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥3,936.7at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio38.8%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio40.4%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio48.4%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio49.2%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio49.8%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE5.9%2025-04-01 → 2026-03-31StandaloneRate of return on equity (5-year summary)
ROE-9.4%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE3.8%2023-04-01 → 2024-03-31vStandaloneRate of return on equity (5-year summary)
ROE4.6%2022-04-01 → 2023-03-31vStandaloneRate of return on equity (5-year summary)
ROE4.3%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued9,451,169at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees1,374at 2026-03-31StandaloneNumber of employees
Employees1,340at 2025-03-31StandaloneNumber of employees
Employees1,307at 2024-03-31vStandaloneNumber of employees
Employees1,314at 2023-03-31vStandaloneNumber of employees
Employees1,344at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2026-03-311268 pure
Real Estate Businessreportable segmentemployeesat 2026-03-311 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,103
ItemContextValueUnit
Net sales on medicine business rev oaCurrentYearDuration_NonConsolidatedMember62208000000JPY
Rent income of real estate rev oaPrior1YearDuration_NonConsolidatedMember115000000JPY
Rent income of real estate rev oaCurrentYearDuration_NonConsolidatedMember99000000JPY
Net salesPrior1YearDuration_NonConsolidatedMember60563000000JPY
Net salesCurrentYearDuration_NonConsolidatedMember62307000000JPY
Cost of sales on medicine business cos exp oaPrior1YearDuration_NonConsolidatedMember43887000000JPY
Cost of sales on medicine business cos exp oaCurrentYearDuration_NonConsolidatedMember46260000000JPY
Cost of real estate rent cos exp oaPrior1YearDuration_NonConsolidatedMember143000000JPY
Cost of real estate rent cos exp oaCurrentYearDuration_NonConsolidatedMember51000000JPY
Cost of salesPrior1YearDuration_NonConsolidatedMember44030000000JPY
Cost of salesCurrentYearDuration_NonConsolidatedMember46312000000JPY
Gross profitPrior1YearDuration_NonConsolidatedMember16532000000JPY
Gross profitCurrentYearDuration_NonConsolidatedMember15995000000JPY
Selling general and administrative expensesPrior1YearDuration_NonConsolidatedMember12401000000JPY
Selling general and administrative expensesCurrentYearDuration_NonConsolidatedMember13355000000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember4131000000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember2639000000JPY
Interest and dividends income noiPrior1YearDuration_NonConsolidatedMember107000000JPY
Interest and dividends income noiCurrentYearDuration_NonConsolidatedMember142000000JPY
Insurance income noiPrior1YearDuration_NonConsolidatedMember84000000JPY
Insurance income noiCurrentYearDuration_NonConsolidatedMember83000000JPY
Other noiPrior1YearDuration_NonConsolidatedMember44000000JPY
Other noiCurrentYearDuration_NonConsolidatedMember46000000JPY
Non operating incomePrior1YearDuration_NonConsolidatedMember235000000JPY
Non operating incomeCurrentYearDuration_NonConsolidatedMember273000000JPY
Interest expenses noePrior1YearDuration_NonConsolidatedMember161000000JPY
Interest expenses noeCurrentYearDuration_NonConsolidatedMember328000000JPY
Commission fee noePrior1YearDuration_NonConsolidatedMember303000000JPY
Commission fee noeCurrentYearDuration_NonConsolidatedMember110000000JPY
Life insurance experses noePrior1YearDuration_NonConsolidatedMember96000000JPY
Life insurance experses noeCurrentYearDuration_NonConsolidatedMember100000000JPY
Other noePrior1YearDuration_NonConsolidatedMember25000000JPY
Other noeCurrentYearDuration_NonConsolidatedMember24000000JPY
Non operating expensesPrior1YearDuration_NonConsolidatedMember586000000JPY
Non operating expensesCurrentYearDuration_NonConsolidatedMember563000000JPY
Ordinary incomePrior1YearDuration_NonConsolidatedMember3780000000JPY
Ordinary incomeCurrentYearDuration_NonConsolidatedMember2349000000JPY
Gain on sales of investment securities eiPrior1YearDuration_NonConsolidatedMember－JPY
Gain on sales of investment securities eiCurrentYearDuration_NonConsolidatedMember118000000JPY
Extraordinary incomePrior1YearDuration_NonConsolidatedMember－JPY
Extraordinary incomeCurrentYearDuration_NonConsolidatedMember118000000JPY
Loss on retirement of noncurrent assets elPrior1YearDuration_NonConsolidatedMember7000000JPY
Loss on retirement of noncurrent assets elCurrentYearDuration_NonConsolidatedMember－JPY
Loss on sales of investment securities elPrior1YearDuration_NonConsolidatedMember－JPY
Loss on sales of investment securities elCurrentYearDuration_NonConsolidatedMember26000000JPY
Loss on valuation of investment securities elPrior1YearDuration_NonConsolidatedMember－JPY
Loss on valuation of investment securities elCurrentYearDuration_NonConsolidatedMember1000000JPY
Provision for litigation loss elPrior1YearDuration_NonConsolidatedMember8744000000JPY
Provision for litigation loss elCurrentYearDuration_NonConsolidatedMember－JPY
Extraordinary lossPrior1YearDuration_NonConsolidatedMember8751000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2025-03-31pass rounding
balance sheet identitynon_consolidated 2026-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · operating cash flownon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flownon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass